Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMedOpen access

A serum-free adipose-conditioned medium delays stem cell senescence and maintains tissue homeostasis via IL-6/STAT3 axis suppression.

Li J., Song L., Song D., Su Z., Bi J., Huo R.

Animal Study on Systemic / IV, published in Stem Cell Res Ther (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
Stem Cell Res Ther (2025)
Country
England
Reported sample size
—
Source database
PubMed
PMID
41316397
PMCID
PMC12664241
DOI
10.1186/s13287-025-04721-8
Citations
2

Abstract (original English)

Background Stem cell exhaustion and cellular senescence are two hallmarks of aging. Mesenchymal stem cells (MSCs), as key players in tissue regeneration, are particularly vulnerable to senescence, which compromises both their endogenous regenerative capacity and their therapeutic efficacy in cell-based applications. Suppressing MSC senescence is therefore essential for developing effective regenerative and anti-aging strategies. Methods We developed a serum-free adipose-conditioned medium (SF-ACM) from in vitro-cultured human adipose explants. Its anti-aging effects were evaluated in oxidative stress-induced and replicative senescence models of human adipose-derived stem cells (ADSCs), assessing proliferation, senescence markers, migration, and trilineage differentiation. Parallel experiments in senescent human dermal fibroblasts (HDFs) examined proliferation, fibrosis, and senescence features. In vivo, male C57BL/6 J mice (4 or 16 months old) with D-galactose-induced and naturally aged mice received intraperitoneal SF-ACM. Aging phenotypes were analyzed in skin, adipose tissue, muscle, kidney, and serum, along with hepatic and renal safety assessments. Results SF-ACM significantly reduced senescence-associated markers, including p16, p21, p53, and SA-β-gal, enhanced Lamin B1 expression, and improved the proliferation, migration, and differentiation capacities of ADSCs. It also

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
Cellular SenescenceSTAT3 Transcription FactorHumansAnimalsAdipose TissueMiceInterleukin-6MaleCulture Media, ConditionedMice, Inbred C57BL

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research